Currently, two isoform-specific HDAC6 inhibitors, ricolinostat (ACY-1215) and ACY-241 are under phase I/II clinical evaluation for the treatment of patients with multiple myeloma and lymphoid malignancies [29]. This evidence concerns the gene HDAC6 and AL amyloidosis.